MELANOMA BRIDGE 2019
Royal Continental Hotel, Naples, Italy
December 5th - December 7th, 2019



Presidents


Paolo A. Ascierto

Paolo A. Ascierto
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy



Corrado Caracò

Corrado Caracò
Chief of advanced melanoma treatment, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy



Igor Puzanov

Igor Puzanov
Professor of Medicine, Director of Early Phase Clinical Trials Program, Melanoma Section Chief and Co-Leader of Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA





Scientific Board


Sanjiv Agarwala

Sanjiv Agarwala
Chief of Medical oncology and Hematology, St. Luke’s University Hospital and Temple University, Bethlehem, Pennsylvania



Paolo A. Ascierto

Paolo A. Ascierto
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy



Carlo Bifulco

Carlo Bifulco
Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon



Lisa H. Butterfield

Lisa H. Butterfield
Vice President of the Parket Institute for Cancer Immunotherapy (PICI) Research Center, Adjunct Professor of Microbiology and Immunology, University of California, San Francisco, California, USA



Corrado Caracò

Corrado Caracò
Chief of advanced melanoma treatment, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy



Sandra Demaria

Sandra Demaria
Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology and Adjunct Professor at Department of Pathology, Weill Cornell Medical College and NYU School of Medicine, New York City, New York, USA


Reinhard Dummer

Reinhard Dummer
Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland



Bernard A. Fox

Bernard A. Fox
Chief of the Laboratory of Molecular and Tumor Immunology, Oregon Health and Science University, Providence Cancer Center, Portland Medical Center, Oregon



Jerome Galon

Jerome Galon
Research Director, National Institute of Health and Medical Research (INSERM), Paris, France




Claus Garbe

Claus Garbe
University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen, Germany



Omid Hamid

Omid Hamid
Chief of Research/ Immuno-Oncology and Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, Los Angeles, California, USA



Giuseppe Masucci

Giuseppe Masucci
Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden




Giuseppe Palmieri

Giuseppe Palmieri
President Italian Melanoma Intergroup (IMI), Head of Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy



Michael Postow

Michael Postow
Memorial Sloane Kettering Cancer Center, New York, New York




Igor Puzanov

Igor Puzanov
Professor of Medicine, Director of Early Phase Clinical Trials Program, Melanoma Section Chief and Co-Leader of Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA


Magdalena Thurin

Magdalena Thurin
Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland



Tara Withington

Tara Withington
Executive Director of Society of Immunotherapy for Cancer (SITC), Milwaukee, Wisconsin, USA




 


For information please contact info@melanomabridge.org